• Mathieu joined Andera Partners in 2014. He is Director in the Andera Life Sciences team.
  • Before joining Andera in 2014, Mathieu worked in an academic research laboratory at the Paris Centre de Recherche Cardiovasculaire (INSERM), where he was in charge of several projects related to tissue engineering and the use of embryonic stem cells in the cardiovascular field.
  • Since joining Andera, Mathieu has worked on a number of investments and supports several portfolio companies. He is an observer on the board of HighLife Medical.
  • Mathieu obtained a Master’s degree in Biotherapies and Tissue Engineering in 2013, which he performed at the University of Paris Descartes.
  • He also holds a postgraduate degree in Finance and Strategy from ESSEC Business School. He speaks French and English.

Investments of Mathieu

04.2023 - andera Life Sciences In portfolio

BioVentrix

Development of clinical solutions for the treatment of patients suffering from heart failure

09.2021 - andera Life Sciences Sold

Amolyt Pharma

Developing therapeutic peptides for rare endocrine and related diseases

11.2015 - andera Life Sciences In portfolio

GAMAMABS

Développement d'anticorps thérapeutiques optimisés pour le traitement du cancer

04.2018 - andera Life Sciences In portfolio

Crescendo Biologics

Plateforme de protéines pour le traitement de cancers

07.2018 - andera Life Sciences In portfolio

Flamingo Therapeutics

Oligonucléotides antisens pour le traitement de cancers 

06.2018 - andera Life Sciences In portfolio

Tricares

Prothèse de valve tricuspide

12.2018 - andera Life Sciences In portfolio

Highlife Medical

Valve mitrale

07.2019 - andera Life Sciences In portfolio

AM Pharma

Protéine recombinante pour le traitement de l'insuffisance rénale aiguë causée par le sepsis

12.2018 - andera Life Sciences In portfolio

T-Knife

Cell therapy for the treatment of cancers

03.2017 - andera Life Sciences In portfolio

MedLumics

Next generation ablation catheter for the treatment of cardiac arrhythmias

09.2015 - andera Life Sciences Sold

Sanifit

Phytic acid for the treatment of cardiovascular calcification

02.2014 - andera Life Sciences In portfolio

Inotrem

Anti-inflammatory peptides for the treatment of sepsis

05.2011 - andera Life Sciences In portfolio

GenKyoTex

Development of inhibitors of enzymes involved in oxydative stress

06.2010 - andera Life Sciences In portfolio

Poxel

Development of small molecules for the treatment of Type 2 diabetes